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Background. Initiation of antiretroviral therapy during primary human immunodeficiency virus (HIV)–1
infection may confer long-term benefit.
Methods. After initiation of zidovudine, lamivudine, abacavir, and amprenavir therapy in patients in the QUEST
cohort, predictors of virological outcome, virological and immunological changes, and adverse events were evaluated
over 48 weeks.
Results. One hundred forty-eight patients started antiretroviral therapy during primary HIV-1 infection with
3 bands on Western Blot (median plasma HIV-1 RNA load, 5.4 log copies/mL; median CD4 cell count, 517
cells/mm3). By week 48, 36% of patients had stopped treatment or were lost to follow-up. Among the 115 patients
receiving follow-up care at week 48 (102 of whom were receiving antiretroviral therapy), the median viral load
decrease was5.4 log copies/mL (interquartile range [IQR],6.4 to3.9 log copies/mL), and the median increase
in CD4 cell count was 147 cells/mm3 (IQR, 1 to 283 cells/mm3); 84.2% of patients had a viral load 50 copies/
mL, and 44.7% of patients had a viral load 3 copies/mL. The median cell-associated RNA level decreased from
3.4 log copies/million PBMCs (IQR, 2.9–4.1 log copies/million PBMCs) to 0.8 log copies/million PBMCs (IQR,
0.5–1.4 log copies/million PBMCs), and the median cell-associated DNA level decreased from 2.8 log copies/
million PBMCs (IQR, 2.4–3.0 log copies/million PBMCs) to 1.6 log copies/million PBMCs (IQR, 1.2–1.9 log
copies/million PBMCs); 33.3% of patients had an undetectable RNA level, and 9.5% of patients had an undetectable
cell-associated DNA level. The median CD8+/CD38++ T cell count decreased from 459 cells/mm3 (IQR, 208–974
cells/mm3) to 33 cells/mm3 (IQR, 19–75 cells/mm3). Baseline CD8+/CD38++ T cell count and cell-associated DNA
level were independent inverse predictors for reaching a viral load3 copies/mL. Eighty-three patients experienced
a serious adverse event (median duration of an adverse event, 15 days).
Conclusions. Initiation of antiretroviral therapy during primary HIV-1 infection was associated with very
significant antiretroviral activity and a decrease in immune activation. Lower baseline CD8+/CD38++ T cell count
and cell-associated DNA level were predictive of achieving a viral load 3 copies/mL.
It is unclear whether initiation of potent antiretroviral
therapy (ART) during primary HIV-1 infection (PHI)
can alter long-term prognosis [1–5]. Early ART can
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decrease HIV-1 load and cellular reservoirs, promote
immune reconstitution, and limit viral heterogeneity
[6–12]. Diagnosis of HIV infection during PHI and
subsequent initiation of ART are for consideration as
a public health strategy to decrease transmission of HIV
infection [13, 14]. Arguments against early treatment
include the risks of drug-induced toxicity and emer-
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gence of resistance in noncompliant patients. Therefore, it is
of interest to evaluate the parameters associated with optimal
responses to early treatment and toxicity, which may affect
responses to treatment.
Herein, we report the baseline characteristics, treatment con-
tinuation rates, virological and immunological responses, and
safety parameters over 48 weeks after ART initiation, together
with the predictors of virological control, in the largest ther-
apeutic cohort of patients who were prospectively enrolled dur-
ing PHI.
METHODS
Study patients. Patients aged 18 years were recruited from
39 health care facilities in 10 countries (including Canada and
Australia and European countries) if they had a negative HIV
ELISA result or 3 bands on Western Blot, in addition to one
of the following characteristics: p24 antigenemia, a PCR result
that was positive for HIV-1 RNA or DNA, or detectable viral
activity by other RNA and DNA quantification methods.
Study design. The design, methods, and outcome measures
of the study have been described previously [15]. Eligible pa-
tients initiated therapy with the following drugs, which were
administered twice daily: 300 mg of zidovudine plus 150 mg
of lamivudine, 300 mg of abacavir, and 1200 mg of amprenavir.
Alteration to this initial regimen was allowed for treatment-
limiting toxicities or compliance issues.
Ethics. All patients provided signed informed consent prior
to study enrollment. Independent local ethics committees re-
viewed and approved the study protocol and its amendments.
An independent data safety and monitoring board monitored
the progress of the trial.
Measurements and evaluations. At enrollment, physicians
recorded the patient’s medical history, risk factors for HIV
acquisition, and symptoms and signs of PHI (with date of
onset) and performed a clinical examination. Baseline blood
sample examination included safety parameters and immu-
nological and virological studies. After enrollment, clinical
status and adverse events were recorded. Safety parameters,
plasma HIV-1 RNA load, and CD4, CD8, and CD8+/CD38++
T cell counts were obtained at regular intervals. Cell-associated
DNA and RNA levels were determined for European and Aus-
tralian patients at baseline and at weeks 4, 12, 24, 36, and 42.
Laboratory methods. Routine complete blood cell counts,
biochemistry values, HIV-1 loads, and CD4 and CD8 cell
counts were measured at central laboratories. The Amplicor
Monitor (Roche Molecular Diagnostics; lower limit of detec-
tion, 400 copies/mL) was used to quantify HIV-1 load. Samples
with HIV-1 loads !400 copies/mL were reanalyzed with the
Ultrasensitive Monitor assay, version 1.5 (limit of detection, 50
copies/mL). The Ultraboosted assay was used to determine viral
loads !3 copies/mL at strategic time points, when the viral load
was !50 copies/mL [7]. CD8+/CD38++ T cell counts were quan-
titated at the HIV Immunology Unit at the Royal Free Hospital
(London, United Kingdom) and at the Centre for Immunology
at National Centre in HIV Epidemiology and Clinical Research
(Sydney, Australia), as previously described [7]. A normal
CD8+/CD38++ T cell count was defined as a count !20 cells/
mm3 [16]. Cell-associated HIV-1 DNA and RNA assays were
performed at the Central Virology Laboratory at Geneva Uni-
versity Hospital (Geneva, Switzerland) (limit of detection, 3
copies/million PBMCs) [7].
Genotypic analysis. Sequence analysis of HIV-1 gag region
and protease coding region and RT-PCR were performed at
baseline (VircoGEN HIV-1 report; Virco).
Statistical methods. Virological and immunological pa-
rameters during follow-up and changes from baseline were
summarized by median and interquartile range (IQR) values,
using data from all patients with measurements available, re-
gardless of whether the patient was receiving ART. Kaplan-
Meier analysis was used to assess changes from baseline in log10
HIV-1 load and cell-associated DNA and RNA levels to account
for the lower limit of detection of assays [17]. Additional anal-
yses of the proportion of patients over time with HIV-1 loads
50 copies/mL, 10 copies/mL, or 3 copies/mL used (1) an
intention-to-treat approach and (2) a “receiving ART” analysis.
Associations between variables were assessed using Spearman’s
rank correlation coefficients. Continuous variables were com-
pared between subgroups using the Mann-Whitney U test. Kap-
lan-Meier estimates were used to examine the probability of
ART discontinuation and change according to various end
points, including the time to achieve an HIV-1 load3 copies/
mL and the occurrence of a serious or grade 3 or 4 adverse
event. Cox proportional hazards regression (stratified by coun-
try) was used to investigate factors associated with these end
points. Results are presented as hazard ratios (HRs) with 95%
CIs.
RESULTS
Patient population and baseline characteristics. From Feb-
ruary 1998 through October 1999, 148 enrolled patients started
ART. The demographic and baseline characteristics of the pa-
tients are shown in table 1. The majority of the patients were
men who had sex with men and were symptomatic during PHI
(90% of patients; fever was reported for 66% of these patients,
malaise for 54%, lethargy for 53%, headache for 44%, myalgia
for 42%, rash for 40%, gastrointestinal symptoms for 39%, and
weight loss for 37%). Treatment was initiated within 1 and 2
weeks of diagnosis in 64% and 83% of patients, respectively.
Patient follow-up and treatment changes. Thirty-three pa-
tients (22.3%) withdrew from follow-up prior to week 48 (12
patients withdrew by choice, 8 withdrew because of adverse
events, 6 were lost to follow-up, and 7 withdrew because of
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Table 1. Demographic and baseline characteristics of 148 pa-
tients with primary HIV-1 infection (PHI).
Baseline characteristics Patients
Recruiting countries
Australia 31 (20.9)
Belgium 4 (2.7)
Canada 10 (6.8)
Denmark 4 (2.7)
France 32 (21.6)
Germany 7 (4.7)
Italy 9 (6.1)
Sweden 7 (4.7)
Switzerland 23 (15.5)
United Kingdom 21 (14.2)
Sex
Male 133 (89.9)
Female 15 (10.1)
Age, mean years (range) 34.6 (20.6–58.7)
Ethnicity
White 140 (94.6)
Asian 2 (1.4)
Black 3 (2.0)
Hispanic 1 (0.7)
Other 2 (1.4)
HIV-1 risk group (n p 146)
Men who have sex with men 105 (71.9)
Heterosexual contact 34 (23.3)
Drug user 5 (3.4)
Occupational 1 (0.7)
Other 1 (0.7)
Symptomatic PHI 132 (89.9)
Duration of symptoms,
median days (range) 21 (2–168)
Time from symptoms to initiation of ART,
median days (range) 18 (8 to 111)
Time from diagnosis to initiation of ART,
median days (range) 6 (6 to 111)
another or unknown reason). Thirty of the patients who with-
drew from follow-up had stopped ART at the last recorded
follow-up visit. Among 115 patients still receiving follow-up
care at week 48, 13 (11.3%), 23 (20%), 78 (67.8%), and 1 (1%)
were receiving 0, 3, 4, and 5 drugs (excluding ritonavir, given
as protease inhibitor booster), respectively, with the following
regimens: nucleoside reverse-transcriptase inhibitors and a pro-
tease inhibitor (administered to 93 patients), a nucleoside re-
verse-transcriptase inhibitor and nonnucleoside reverse-tran-
scriptase inhibitors (administered to 2 patients), and nucleoside
reverse-transcriptase inhibitors alone (administered to 7 pa-
tients). Fifty-eight patients continued to receive their initial
ART regimen, and 86, 85, and 73 patients continued to receive
abacavir, zidovudine plus lamivudine, and amprenavir, respec-
tively. At week 48, 20 (17.4%) of 115 patients had discontinued
ART for 7 days (8 patients discontinued ART because of
noncompliance, 5 because of adverse events, 2 by choice, and
5 because of an other or unknown reason), and 62 (53.9%) of
115 patients had changed their initial regimen (defined as dis-
continuation of any drug for 7 days or addition of a new
drug).
Figure 1 shows Kaplan-Meier cumulative proportions over
time for 3 outcomes, including study withdrawal (outcome A;
33 patients), study withdrawal or discontinuation of ART for
7 days (outcome B; 53 patients), and study withdrawal or
regimen change (outcome C; 95 patients), with percentages at
week 48 of 22.3%, 35.8%, and 64.2%, respectively. The rate of
discontinuation or change of ART was high during the first 2
months and decreased over time ( , , andPp .22 Pp .006
, by Poisson regression for linear trend in rate of out-P ! .001
comes A, B, and C, respectively, over four 12-week periods).
In a Cox model of the association of baseline factors with
outcome B, stratified by country of recruitment, older age,
being a man who has sex with men, and higher baseline viral
load were independently associated with a lower risk of study
withdrawal and/or ART discontinuation (adjusted HR, 0.93
[95% CI, 0.88–0.97; ], for every year older in age; ad-P ! .001
justed HR, 0.76 [95% CI, 0.59–0.98; ], for every logPp .036
higher in viral load; adjusted HR, 0.47 [95% CI, 0.23–0.99;
], for being a man who has sex with men vs. otherPp .046
sexual preferences); no association was found between study
withdrawal and/or discontinuation of ART and baseline CD4
cell count or presence of symptoms of PHI ( , for adjustedP 1 .5
HRs).
Baseline plasma viral load and immunological parameters.
The median HIV-1 load was 5.4 log copies/mL (range, 2.1–7.9
log copies/mL), and the median CD4 cell count was 514 cells/
mm3 (range, 162–1380 cells/mm3) (table 2). Plasma viremia
was inversely correlated with CD4 cell count (Spearman’s cor-
relation: ; ). Patients with symptoms tendedrp -0.41 P ! .001
to have higher viral loads than did patients who did not have
symptoms (5.5 log copies/mL vs. 4.9 log copies/mL; ,Pp .13
by Mann-Whitney U test). More recent symptom onset was
associated with higher viral load and lower CD4 cell count.
Correlations of time since symptom onset with viral load and
CD4 cell count were 0.35 ( ) and 0.17 ( ),P ! .001 Pp .052
respectively.
Baseline cell-associated RNA and DNA levels and corre-
lation with viral load and CD4 cell counts. Cell-associated
HIV-1 RNA and DNA levels were measured in 114 patients.
The median HIV-1 RNA level was 3.4 log copies/million
PBMCs (range, 0.9–5.9 log copies/million PBMCs), and the
median cell-associated HIV-1 DNA level was 2.8 log copies/
million PBMCs (range, 1.2–4.0 log copies/million PBMCs) (ta-
ble 2); these levels strongly correlated with HIV-1 load (Spear-
man’s correlation: and , for RNA;rp 0.88 P ! .001 rp 0.64
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Figure 1. Cumulative percentage of patients according to study withdrawal (A), study withdrawal or discontinuation of all antiretroviral therapy
(ART) for 7 days (B), and study withdrawal or discontinuation of any ART drug for 7 days or addition of a new drug (C), by number of weeks
after initiation of ART.
and , for DNA). CD4 cell count was inversely correlatedP ! .001
with cell-associated RNA level ( ; ) and cell-rp0.44 P ! .001
associated DNA level ( ; ).rp0.31 Pp .001
Baseline genotypic resistance. Genotyping performed for
132 patients revealed thymidine-associated mutations in 5 pa-
tients (4%), and 9 patients (7%) harbored other nucleoside re-
verse-transcriptase inhibitor–associated mutations (3 patients
had mutations in codon 215, 3 had mutations in codon 184,
and 3 had mutations in codon 41). One patient had a primary
protease inhibitor–associated mutation, and none had nonnu-
cleoside reverse-transcriptase inhibitor–associated mutations.
Changes in plasma viral load and immunological param-
eters after initiation of ART. HIV-1 load decreased over 48
weeks after ART initiation (table 2 and figure 2). Median
changes adjusted for the limit of detection were 1.8 log
copies/mL (IQR, 2.5 to 1.4 log copies/mL) at week 2,
3.4 log copies/mL (IQR, 4.2 to 2.7 log copies/mL) at
week 12, and 5.4 log copies/mL (6.4 to 3.9 log copies/
mL) at week 48. Corresponding changes unadjusted for the
limit of detection at weeks 2, 12, and 48 were1.8 log copies/
mL, 3.2 log copies/mL, and 4.7 log copies/mL, respec-
tively. At week 48, 96 (84.2%) of 114 patients had a viral load
50 copies/mL, 71 (62.3%) of 114 patients had a viral load
10 copies/mL, and 51 (44.7%) of 114 patients had a viral
load 3 copies/mL. CD4 cell count increased rapidly during
the first 2 weeks of treatment, with little further increase at
week 2. The median change in CD4 cell count at week 2 was
+124 cells/mm3 (IQR, 25 to +267 cells/mm3), at week 12
was +152 cells/mm3 (IQR, 0 to +275 cells/mm3), and at week
48 was +147 cells/mm3 (IQR,1 to +283 cells/mm3), at which
time the median CD4 cell count was 677 cells/mm3 (IQR,
520–843 cells/mm3). CD4 percentage also increased. Median
changes in CD4 percentage from baseline were +9% (IQR,
+3% to +14%) at week 2, +9% (IQR, +4% to +17) at week
12, and +12% (IQR, +6% to +19%) at week 48 (table 2).
The median CD8+/CD38++ T cell count decreased to 33 cells/
mm3 (IQR, 19–75 cells/mm3) at week 48 (table 2).
Changes in cell-associated HIV-1 RNA and DNA levels after
initiation of ART. Changes of cell-associated HIV-1 RNA and
DNA levels are shown in table 2 and figure 2. The cell-associated
RNA level decreased rapidly during the first 4 weeks in parallel
with HIV-1 load, with little further decrease thereafter. At week
42, the median RNA level was 0.8 log copies/million PBMCs
(IQR, 0.48–1.43 log copies/million PBMCs) among 63 patients.
The cell-associated DNA level decreased gradually over 42
weeks to reach a median level of 1.58 log copies/million PBMCs
(IQR, 1.18–1.90 log copies/million PBMCs) among 63 patients.
At week 42, levels !3 log copies/million PBMCs were noted in
21 (33.3%) of 63 patients and 6 (9.5%) of 58 patients for cell-
associated RNA and DNA, respectively. Levels of cell-associated
RNA and DNA at week 42 were associated with the viral load
at week 48 ( , for cell-associated RNA level, andrp 0.42 rp
, for cell-associated DNA level; ). Baseline cell-as-0.43 P ! .001
sociated DNA levels were also associated with cell-associated
DNA levels at week 42 ( ; ). Two patientsrp 0.43 Pp .001
achieved undetectable levels according to all 3 measures (cell-
associated RNA and DNA levels !3 log copies/million PBMCs
and viral load 3 copies/mL) at week 42.
Baseline factors and time to achieve an HIV-1 load 3
copies/mL. Cumulative proportions of 78 patients with an
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Table 2. Baseline values, week 48 values, and changes from baseline to week 48, for virological and immunological parameters
among all patients who continued to receive follow-up care.
Variable
Baseline Week 48a Change from baseline to week 48b
No. of
patients for
whom data
were available Median (IQR)
No. of
patients for
whom data
were available Median (IQR)
No. of
patients for
whom data
were available Median (IQR)
Plasma HIV-1 RNA load, log copies/mL 146 5.4 (4.9–6.2) 114 0.7 (0.5–1.5) 112 5.4c (6.4 to 3.9)
CD4 cell count, cells/mm3 139 514 (399–674) 110 677 (520–843) 104 +147 (1 to +283)
CD4 percentage 139 26 (19–35) 110 40 (32–43) 104 +12 (+6 to +19)
CD8 cell count, cells/mm3 139 1035 (657–1620) 110 647 (447–924) 104 389 (987 to 35)
CD4:CD8 cell count 139 0.5 (0.3– 0.8) 110 1.0 (0.8–1.4) 104 +0.5 (+0.2 to +0.8)
CD8+/38++ cell count, cells/mm3 127 459 (208–974) 101 33 (19–75) 92 410 (933 to 136)
Cell-associated RNA level, log copies/
million PBMCs 114 3.4 (2.9–4.1) 63 0.8 (0.5–1.4) 55 2.6c (3.3 to 2.0)
Cell-associated DNA level, log copies/
million PBMCs 113 2.8 (2.4–3.0) 63 1.6 (1.2–1.9) 54 1.1c (1.6 to 0.8)
NOTE. IQR, interquartile range.
a Cell-associated RNA and DNA levels were measured at week 42.
b for all.P ! .001
c Adjusted for assay limit of detection.
HIV-1 load 3 copies/mL were 1.5%, 11.1%, 32.8%, 55.2%,
and 63.4% by weeks 12, 20, 28, 36, and 48, respectively. In
univariable Cox models stratified by country, baseline viral load,
cell-associated RNA level, cell-associated DNA level, and CD8+/
CD38++ T cell count were each inversely associated with time
to achieve a viral load 3 copies/mL (HRs for every 1 log
higher value for each parameter were 0.79 [95% CI, 0.64–0.98]
for viral load, 0.29 [95% CI, 0.17–0.50] for cell-associated DNA
level, 0.60 [95% CI, 0.44–0.80] for cell-associated RNA level,
and 0.55 [95% CI, 0.32–0.94] for CD8+/CD38++ T cell count);
CD4 cell count was not inversely associated with time to achieve
a viral load 3 copies/mL (HR for every 100 cells higher, 1.04;
95% CI, 0.94–1.15). In a multivariable model, baseline CD8+/
CD38++ T cell count and cell-associated DNA level were in-
dependent predictors of a viral load 3 copies/mL among 103
patients (adjusted HR for every 1 log higher, 0.30 [95% CI,
0.18–0.51]; , for cell-associated DNA; HR, 0.47 [95%P ! .001
CI, 0.25–0.86]; , for CD8+/CD38++ T cell count).Pp .016
Suppression of plasma viremia according to “intention-to-
treat” and “receiving ART” analyses. Figure 3 shows the pro-
portion of patients with viral loads50 copies/mL,10 copies/
mL, and 3 copies/mL, by week of follow-up, using (1) an
“intention-to-treat” analysis, in which all 148 patients were
included at each time point, with missing data counted as “fail-
ure;” and (2) a “receiving ART” analysis, in which only patients
receiving any type of ART were included at the time of viral
load measurement. Using an intention-to-treat analysis, 64.9%
(95% CI, 57.2%–72.6%), 48.0% (95% CI, 39.9%–56.0%), and
34.5% (95% CI, 26.8%–42.1%) of all 148 patients had viral
loads 50 copies/mL, 10 copies/mL, and 3 copies/mL at
week 48, respectively. Corresponding percentages for the re-
ceiving ART analysis were 94.0% (95% CI, 87.4%–97.8%),
69.05 (95% CI, 59.0%–77.9%), and 49.0% (95% CI, 38.9%–
59.2%) among 100 patients. Overall, only 5 patients reached a
viral load 1400 copies/mL during weeks 28–48 while receiving
ART.
Safety and adverse events. Eighty-three clinical adverse
events classified as grade 3 or 4 or serious adverse events oc-
curred among 49 patients during the 48 weeks after ART ini-
tiation. The most common clinical adverse events were de-
pression and/or attempted suicide (accounting for 11% of all
serious adverse events or grade 3 or 4 clinical adverse events),
rash (9%), vomiting (8%), nausea (7%), fever (6%), diarrhea
(6%), and hypersensitivity to abacavir (6%). Of these 83 adverse
events, 38 were considered to be related to study drug. One
death due to gastrointestinal hemorrhage was considered to be
unrelated to study drug. Ninety-three grade 3 or 4 laboratory
abnormalities occurred among 45 patients (increased alanine
aminotransferase [accounting for 19% of all grade 3 or 4 lab-
oratory adverse events], amylase [19%], aspartate aminotrans-
ferase [12%], and creatine phosphokinase levels [15%] and
neutropenia [11%]). Cumulative percentages of patients having
a serious or grade 3 or 4 adverse event during 4, 12, 24, and
48 weeks of ART initiation were 23.9%, 38.0%, 45.6%, and
58.5%, respectively. The median duration of an adverse event
was 15 days, with 90% of adverse events occurring for !65
days. Thirty-two adverse events (in 22 patients) resulted in
interruption (14 patients) or discontinuation (18 patients) of
a drug. No patient developed AIDS during the study period.
DISCUSSION
Herein, we report the largest prospective therapeutic study of
PHI. The majority of patients were men who have sex with
386 • CID 2007:45 (1 August) • HIV/AIDS
Figure 2. Median changes from baseline in plasma HIV-1 RNA load, cell-associated RNA and DNA levels, and CD4 cell count, by number of weeks
after initiation of antiretroviral therapy (ART). Data include all patients who continued to receive follow-up care. Changes in plasma HIV-1 RNA load
were adjusted for assay limit of detection.
men and were symptomatic during PHI. By week 48, 36% of
the patients who had started receiving ART were either not
receiving treatment or lost to follow-up, with an initial high
rate of treatment change, which stabilized later during the study.
The vast majority of patients who stopped receiving ART pre-
maturely had undetectable HIV-1 loads when therapy was in-
terrupted. ART initiation was associated with decreases in HIV-
1 load and cell-associated RNA and DNA levels and an
improvement in immunological parameters. Baseline CD8+/
CD38++ T cell count and cell-associated DNA level were in-
dependent predictors for achieving a viral load 3 copies/mL.
Toxicity was generally reversible.
This study provides important information regarding the
feasibility of starting quadruple ART in a large cohort of pa-
tients with PHI. Previous studies, which generally used 3 drugs,
have shown treatment discontinuation rates of 19%–50% at 1
year [18–21]. A recent diagnosis of HIV infection, a rapid life-
changing decision, clinical symptoms, and future rather than
immediate administration of ART may compound the prob-
lems of treatment-related toxicity and high pill burden when
comparing treatment discontinuation rates between patients
with acute infection and those with chronic infection [22]. Kost
et al. [22] revealed a higher number of patients stopping a
similar ART regimen when they were treated during early in-
fection, compared with those treated during chronic infection.
Among newly infected patients, nonadherence and intolerance
to adverse effects of therapy were the main reported reasons
for stopping treatment. The availability of newer drugs with
lower toxicities and pill counts may positively impact patients’
adherence in future studies.
Our results confirm those from previous smaller studies of
PHI that reveal the possibility of achieving an undetectable
HIV-1 load [18–24]. The extent of virological control after
ART initiation was further exemplified by the percentages of
patients receiving ART at week 48 who had HIV-1 loads 50
copies/mL, 10 copies/mL, and 3 copies/mL, a median de-
crease in HIV-1 load of 5.4 log copies/mL, and an HIV-1 load
of 0.7 log copies/mL. Even during a conservative intention-
to-treat analysis (with missing data counted as “failure”), 64%
of the patients had an HIV-1 load 50 copies/mL at week
48—a result comparable to that found during chronic infec-
tion [25].
Baseline parameters were helpful in forecasting virological
outcome. Cell-associated HIV-1 RNA and DNA levels are in-
direct markers of treatment efficacy [7, 18]. Previous studies,
including a study by Garrigue et al. [26], have revealed a median
HIV-1 mRNA level of 1.7 log copies/million PBMCs and de-
tectable mRNA levels after 12 months of ART in some aviremic
patients with PHI who received ART and in all patients with
chronic infection who received ART [7, 20, 27–29]. We extend
these results by revealing that plasma replication was dramat-
ically decreased overall, because 33% of the patients had viral
loads 3 copies/mL, and that the overall cell-associated RNA
level decreased from 2.6 log copies/million PBMCs to 0.8 log
copies/million PBMCs.
When looking at cell-associated DNA level, which reflects
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Figure 3. Percentage of patients with plasma HIV-1 RNA loads (VL) 50 copies/mL, 10 copies/mL, and 3 copies/mL. The solid line represents
data according to an intention-to-treat analysis, with missing data counting as “failure.” The dotted line represents a “receiving antiretroviral therapy
(ART)” analysis. The numbers of patients in the “receiving ART” analysis were 146, 133, 126, 120, 113, 104, 111, and 100 at weeks 0, 4, 8, 12, 20,
28, 36, and 48, respectively.
the reservoir size, we found a median decrease of the cell-
associated DNA level of 1.1 log copies/million PBMCs and a
cell-associated DNA level of 1.6 log copies/million PBMCs at
the end of year 1. Previous studies of PHI have described a
decrease of the cell-associated DNA level of ∼1.0 log after 18
months of ART, compared with the one-half log decrease and
absence of undetectable levels during chronic infection [7, 20,
26, 27, 30–32]. Garrigue et al. [26] reported that, after 1 year
of ART, cell-associated DNA levels were 2.0 log copies/million
PBMCs, with 1 of 22 patients having a cell-associated DNA
level !10 copies/million PBMCs; these findings contrast our
figure of 6 patients (9.5%) with cell-associated DNA levels3
copies/million PBMCs. Five of these 6 patients had a viral load
!10 copies/mL at the time of proviral measurement. These
patients did not differ in terms of baseline CD4 cell count and
HIV-1 load from those who had detectable cell-associated DNA
levels. Our results suggest that lower levels of cell-associated
DNA are achievable with ART initiation during PHI than with
ART initiation during chronic infection [7, 31, 32].
Our data also illustrate the changes in immune activation.
Normalization of the CD8+/CD38++ T cell count occurred in
28 (27.7%) of 101 patients at week 48. These cell counts de-
creased initially in parallel with viral load and continued to
decrease in patients achieving a viral load 50 copies/mL—
but not in patients with a viral load3 copies/mL—and could,
therefore, represent a sensitive indicator of residual viral rep-
lication [33, 34]. Patients with an undetectable cell-associated
RNA level at week 42 indeed had lower CD8+/CD38++ T cell
counts at weeks 36 and 48, compared with those who had a
detectable cell-associated RNA level at week 42. The initial fol-
low-up of 6 patients who had stopped treatment prematurely
suggested that the CD8+/CD38++ T cell count tended to increase
with subsequent viral load rebound (data not shown).
Safety is an important factor to consider when initiating early
treatment. Grade 3 or 4 clinical and laboratory severe adverse
events occurred in a substantial proportion of patients but were
generally reversible, as previously reported [22]. The incidence
of hypersensitivity to abacavir (3%) was comparable to that in
other studies. The rate of severe adverse events in our study
compares with that in a previous study in which 17 of 39
patients with acute and chronic infection experienced 19 severe
adverse events; significant depression accounted for 2 severe
adverse events [22]. In a French cohort study of PHI, 124
patients (51%) described having experienced at least 1 adverse
event, and 19% of these events were reported as mood disorder
[35]. The 14 psychiatric severe adverse events in our study were
not considered to be related to study medication. Strong past
confounding factors were present in 11 of 13 patients, revealing
the potential for serious psychiatric events during the imme-
diate postseroconversion phase in patients with a previous psy-
chiatric history.
In conclusion, we have described the first-year outcome of
a large cohort of patients who initiated a protease inhibitor–
based, 4-drug ART regimen during PHI. Our results are very
388 • CID 2007:45 (1 August) • HIV/AIDS
encouraging for achieving a very low HIV-1 load, considering
the virological parameters in patients receiving ART, unde-
tectable cell-associated RNA and DNA levels in a substantial
proportion of patients and predictive value of proviral DNA,
and CD8+/CD38++ T cell count. This cohort data may serve as
reference when using newer, simpler regimens with lower acute
toxicity and activity during the preintegration stage. Future
studies may also explore whether long-term treatment is as-
sociated with a continuous decrease of the viral reservoir and
a potential absence of viral rebound after very prolonged ART.
QUEST STUDY GROUP
Recruiting centers. D. Baker, M. Bloch, D. Smith, R. Fin-
laysson, P. Grey, D. Smith, and D. A. Cooper (Sydney, Aus-
tralia); P. Hermanns, K. Kabeya, and N. Clumeck (Brussels,
Belgium); M. Harris and J. Montaner (Vancouver, Canada); C.
Tsoukas (Montreal, Canada); L. Mathiesen and J. Gerstoft (Hvi-
dovre, Denmark); B. Hoen (Besancon, France); P. M. Girard,
J. Modai, A. G. Saimot, D. Sereni, J. F. Delfraissy, and C. Ka-
tlama (Paris, France); F. Raffi (Nantes, France); C. Aquilina
(Toulouse, France); F. Caron (Rouen, France); P. Canton and
T. May (Nancy, France); J. M. Chennebault (Angers, France);
S. Staszewski (Frankfurt, Germany); H. J. Stellbrink (Hamburg,
Germany); G. Tambussi and A. Lazzarin (Milan, Italy); S. Lind-
back, A. Blaxhult, and H. Gaines (Stockholm, Sweden); M. C.
Bernard, B. Hirschel, and L. Perrin (Geneva, Switzerland); P.
Vernazza (St. Gallen, Switzerland); K. Wolf and M. Battegay
(Basel, Switzerland); R. Weber (Zurich, Switzerland); S. Kin-
loch-de Loes, M. Youle, M. Tyrer, S. Bhagani, M. A. Johnson,
C. Higgs, D. Hawkins, and B. Gazzard (London, United King-
dom); M. J. Fisher (Brighton, United Kingdom); and A. Fried-
man (Cardiff, United Kingdom).
GlaxoSmithKline QUEST team. V. Mallet, S. Turkish, S.
Fortes, H. Maseruka, H. McDade, H. Steel, and L.-E. Goh
(Greenford, United Kingdom).
GlaxoSmithKline monitors. M. Haberl and J. Young (Aus-
tralia); D. Luyts and I. van Steenberg (Belgium); S. Pratt and
T. Russell (Canada); L. Beauvais and J. M. Vauthier (France);
M. Sikora (Germany); C. Gussetti, C. M. Anghileri, V. Piva,
and D. Fendt (Italy); G. Larsson (Sweden); C. Python, I. Schau-
wecker, and E. Gremlich (Switzerland); and K. Studdard, P.
Humphreys, and U. Loughrey (United Kingdom).
Roche Molecular Systems. B. Dale and A. Capt (Alameda,
CA).
Virco. W. Verbiest and P. Stoffels (Mechelen, Belgium).
Laboratory support. L. Wegmann, S. Yerly, and L. Perrin
(Laboratory of Virology, Geneva University Hospital, Geneva,
Switzerland); J. Zaunders, P. Cunningham, and A. Kelleher
(Centre for Immunology, St. Vincent’s Hospital, NCHECR
University of New South Wales, Sydney, Australia); and S. Mar-
tins and G. Janossy (HIV Immunology Laboratory, Department
of Immunology and Molecular Pathology, Royal Free and Uni-
versity College Medical School, London, United Kingdom).
Data safety and monitoring board. M. Schechter (Can-
ada), I. Weller (United Kingdom), R. Luethy (Switzerland), and
J. M. Molina (France).
Statistical analysis. F. C. Lampe and A.N. Phillips.
QUEST core group (steering committee). S. Kinloch-de
Loes, L. Perrin, D. Cooper, B. Hoen, B. Autran, A.N. Phillips,
J. Andersson, A. Sonneborg, and C. Tsoukas.
AUTHOR AFFILIATIONS
1Department of Infectious Diseases, University Medical Centre,
Besancon, and 2Department of Internal Medicine, St. Louis
Hospital, and 3Service des Maladies Infectieuses et Tropicales,
Centre Hospitalier Universitaire Saint-Louis, Paris, France; 4Na-
tional Centre in HIV Epidemiology and Clinical Research, Uni-
versity of New South Wales and St. Vincent’s Hospital, Sydney,
New South Wales, and 5Taylor Square Private Clinic, Surry
Hills, Sydney, Australia; Departments of 6Primary Care and
Population Sciences, 7Immunology and Molecular Pathology,
and 8Infection and Immunity, Royal Free Center for HIV Med-
icine, Royal Free and University College Medical School, and
9Kobler Centre, Chelsea & Westminster Hospital, London, and
10GlaxoSmithKline Research and Development, Greenford,
United Kingdom; 11Laboratory of Virology, Division of Infec-
tious Diseases, Geneva University Hospital, Geneva, and 12Di-
vision of Infectious Diseases, Department of Internal Medicine,
University Hospital, Zurich, Switzerland; 13Department of In-
fectious Diseases, St. Pierre Hospital, Brussels, Belgium; 14De-
partment of Infectious Diseases, Karolinska University Hos-
pital, Stockholm, Sweden; 15John Ruedy Immune Deficiency
Clinic, St. Paul’s Hospital, University of British Columbia, Van-
couver, Canada; 16IPM Study Center, Hamburg, and 17Klinikum
der JW Goethe Universitat, Zentrum der Inneren Medizin,
Frankfurt, Germany; 18Clinic of Infectious Diseases, San Raf-
faele Scientific Institute, Milan, Italy; and 19Hvidovre Hospital,
Hvidovre, Denmark.
Acknowledgments
We thank scientists, for their advice, and the physicians and nurses, for
patient referral and clinical care. Above all, we thank all of the patients
who participated in the study.
Financial support. GlaxoSmithKline funded the study and provided
study drug.
Manuscript preparation. L.-E.G. contributed to the design of the study
and was also responsible for its implementation at all of the study sites.
Data analysis was performed by F.C.L.
Potential conflicts of interest. The following authors have received
reimbursement or fees from various pharmaceutical or vaccine companies
for attending a symposium, speaking at or chairing a symposium, per-
forming research, or consulting: S.K-d. L. from Bristol-Myers Squibb,
GlaxoSmithKline, Abbott, Gilead, Oxxon Therapeutics, and Tibotec; B.H.
from GlaxoSmithKline France and United States, Roche France, Gilead
Science France, Tibotec France, Abbott France, Boehringer-Ingelheim
HIV/AIDS • CID 2007:45 (1 August) • 389
France, and Bristol-Myers Squibb France; D.A.C. from GlaxoSmithKline;
F.L. from GlaxoSmithKline and Oxxon Therapeutics; L.P. from Glaxo-
SmithKline, Roche Diagnostic, and Abbott; A.N.P. from Roche, Glaxo-
SmithKline, Abbott, Boehringer-Ingelheim, Gilead, Tibotec, and Oxxon
Therapeutics; S.L. from Abbott, Merck Sharp & Dome, GlaxoSmithKline,
Bristol-Myers Squibb, Boehringer Ingelheim, and Roche; B.G. from
GlaxoSmithKline, Bristol-Myers Squibb, Gilead Sciences, Johnson & John-
son, and Merck Pharmaceuticals; J.M. from Abbott, Amgen, Argos Ther-
apeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences,
GlaxoSmithKline, Hoffmann-La Roche, Janssen-Ortho, Merck Frosst,
Pfizer, Sanofi, Schering, Serono, Theratechnologies, Tibotec, and Trimeris;
H.-J.S. from Bristol-Myers Squibb, Hoffman-La Roche, Tibotec/Janssen-
Cilag, GlaxoSmithKline, Gilead, Abbott, Pfizer, Merck, and Boehringer In-
gelheim; A.L. from GlaxoSmithKline, Bristol-Myers Squibb, Abbott, Roche,
Gilead, Pfizer, Tibotec, Boehringer Ingelheim, and Merck; L.M. from Boeh-
ringer Ingelheim, GlaxoSmithKline, Merck Sharp & Dohme, Roche, and
Swedish Orphan A/s; R.F. from Abbott, Britol-Myers Squibb, Merck Sharp
& Dohme, GlaxoSmithKline, Roche, Gilead, and Boehringer Ingelheim;
R.W. from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead
Sciences, GlaxoSmithKline, Merck, Pfizer, Hoffman-La Roche, and TRB
Chemedica; G.J. from GlaxoSmithKline; and N.C. from Abbott, Boehringer
Ingelheim, Merck Sharp & Dohme, Roche, GlaxoSmithKline, and Tibotec.
L-E.G. is a full-time clinical researcher at GlaxoSmithKline and holds stock
options. L.W. and D.P.: no conflicts.
References
1. Sterling TR, Chaisson RE, Keruly J, Moore RD. Improved outcomes
with earlier initiation of highly active antiretroviral therapy among
human immunodeficiency virus–infected patients who achieve durable
virological suppression: longer follow-up of an observational cohort
study. J Infect Dis 2003; 188:1659–65.
2. Smith DE, Walker B, Cooper DA, Rosenberg ES, Kaldor JM. Is anti-
retroviral treatment of primary HIV infection clinically justified on the
basis of current evidence? AIDS 2004; 18:709–18.
3. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1
after early treatment of acute infection. Nature 2000; 407:523–6.
4. Kinloch-de Loes S. Treatment of acute HIV-1 infection: is it coming
of age? J Infect Dis 2006; 194:721–4.
5. Berrey MM, Schaker T, Collier AC, et al. Treatment of primary human
immunodeficiency virus type 1 infection with potent antiretroviral
therapy reduces frequency of rapid progression to AIDS. J Infect Dis
2001; 183:1466–75.
6. Hoen B, Dumon B, Harzic M, et al. Highly active antiretroviral treat-
ment initiated early in the course of symptomatic primary HIV-1 in-
fection: results of the ANRS 053 Trial. J Infect Dis 1999; 180:1342–6.
7. Yerly S, Perneger TV, Vora S, Hirschel B, Perrin L. Decay of cell-
associated HIV-1 DNA correlates with residual replication in patients
treated during acute HIV-1 infection. AIDS 2000; 14:2805–12.
8. Strain MC, Little SJ, Daar ES, et al. Effect of treatment, during primary
HIV infection, on establishment and clearance of cellular reservoirs of
HIV-1. J Infect Dis 2005; 191:1410–8.
9. Kaufmann GR, Zaunders JJ, Cunningham P, et al. Rapid restoration
of CD4 T cell subsets in subjects receiving antiretroviral therapy during
primary HIV-1 infection. AIDS 2000; 14:2643–51.
10. Altfeld M, Rosenberg, ES, Shankarappa R, et al. Cellular immune re-
sponses and viral diversity in individuals treated during acute and early
HIV-1 infection. J Exp Med 2001; 193:169–80.
11. Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active anti-
retroviral therapy for acute HIV infection preserves immune function
of CD8+ and CD4+ T lymphocytes. Proc Nat Acad Sci USA 2000; 97:
3382–7.
12. Goh LE, McDade H, Kinloch S, et al. The QUEST trial, a paradigm
of HIV collaborative research. Nat Med 2000; 6:1194.
13. Pilcher CD, Chuan Tien H, Eron JJ, et al. Brief but efficient: acute
HIV infection and the sexual transmission of HIV. J Infect Dis 2004;
189:1785–92.
14. Cohen MS, Pilcher CD. Amplified HIV transmission and new ap-
proaches to HIV prevention. J Infect Dis 2005; 191:1391–3.
15. Kinloch-de Loes S, Hoen B, Smith DE. Impact of therapeutic im-
munization on HIV-1 viremia after discontinuation of antiretroviral
therapy initiated during acute infection. J Infect Dis 2005; 192:607–17.
16. Tilling R, Kinloch S, Goh LE, et al. Parallel decline of CD8+/CD38++
T cells and viraemia in response to quadruple highly active antiret-
roviral therapy in primary HIV infection. AIDS 2002; 16:589–96.
17. Marschner IC, Betebsky RA, DeGruttola V, Hammer SM, Kuritzkes
DR. Clinical trials using HIV-1 RNA–based primary endpoints: statis-
tical analysis and potential biases. J Acquir Immune Defic Syndr Hum
Retroviral 1999; 20:220–7.
18. Zaunders JJ, Cunningham PH, Kelleher AD, et al. Potent antiretroviral
therapy of primary human immunodeficiency virus type 1 (HIV-1)
infection: partial normalization of T lymphocyte subsets and limited
reduction of HIV-1 DNA despite clearance of plasma viremia. J Infect
Dis 1999; 180:320–9.
19. Smith D, Berrey M, Robertson M, et al. Virological and immunological
effects of combination antiretroviral therapy with zidovudine, lami-
vudine, and indinavir during primary human immunodeficiency virus
type 1 infection. J Infect Dis 2000; 182:950–4.
20. Markowitz M, Vesanen M, Tenner-Racz K, et al. The effect of com-
mencing combination antiretroviral therapy soon after human im-
munodeficiency virus type 1 infection on viral replication and antiviral
immune responses. J Infect Dis 1999; 179:527–37.
21. Nui MT, Bethel J, Holodniy M, Standiford HC, Schnittman SM; DATRI
002 Study Group. Zidovudine treatment in subjects with primary
(acute) human immunodeficiency virus type 1 infection: a randomized
double-blind placebo-controlled trial. J Infect Dis 1998; 178:80–91.
22. Kost RG, Hurley A, Zhang L, et al. Open-label phase II trial of am-
prenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and
chronically HIV-1–infected patients. J Acquir Immune Defic Syndr
2001; 26:332–9.
23. Lillo FB, Ciuffreda D, Veglia F, et al. Viral load and burden modification
following early antiretroviral therapy of primary HIV-1 infection. AIDS
1999; 13:791–6.
24. Lisziewicz J, Jessen H, Finzi D, Siliciano RF, Lori F. HIV-1 suppression
by early treatment with hydroxyurea, didanosine, and a protease in-
hibitor. Lancet 1998; 352:199–200.
25. Eron J Jr, Yeni P, Gathe J, et al. The KLEAN study of fosamprenavir-
ritonavir versus lopinavir-ritonavir, each in combination with abacavir-
lamivudine, for initial treatment of HIV infection over 48 week: a
randomized non-inferiority trial. Lancet 2006; 368:476–82.
26. Garrigue I, Pellegrin I, Hoen, B, et al. Cell-associated HIV-1 DNA
quantification after HAART-treated primary infection in patients with
persistently undetectable plasma HIV-1 RNA. AIDS 2000; 14:2851–6.
27. Ramratnam B, Ribeiro R, He T, et al. Intensification of antiretroviral
therapy accelerates the decay of the HIV-1 latent reservoirs and de-
creases, but does not eliminate ongoing virus replication. J Acquir
Immune Defic Syndr 2004; 35:33–7.
28. Ramratnan B, Mittler JE, Zhang L, et al. The decay of the latent res-
ervoir of replication-competent HIV-1 is inversely correlated with the
extent of residual viral replication during prolonged anti-retroviral
therapy. Nat Med 2000; 6:82–5.
29. Siciliano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies
confirm the stability of the latent reservoir for HIV-1 in resting CD4+
T cells. Nat Med 2003; 9:727–8.
30. Chun TW, Nickle DC, Justemenet JS, et al. HIV-infected individuals
receiving effective antiviral therapy for extended periods of time con-
tinually replenish their viral reservoirs. J Clin Invest 2005; 115:3250–5.
31. Ngo-Giang-Huong N, Deveau C, Da Silva C, et al. Proviral HIV-1
DNA in subjects followed since primary HIV-1 infection who suppress
plasma viral load after one year of highly active antiretroviral therapy.
AIDS 2001; 15:665–73.
32. Viard JP, Burgard M, Hubert JB, et al. Impact of 5 years of maximally
successful highly active antiretroviral therapy on CD4 cell count and
HIV-1 DNA level. AIDS 2004; 18:45–9.
390 • CID 2007:45 (1 August) • HIV/AIDS
33. Garcia F, Vidal C, Plana M, et al. Residual low-level viral replication
could explain discrepancies between viral load and CD4+ cell responses
in human immunodeficiency virus–infected patients receiving antiret-
roviral therapy. Clin Infect Dis 2000; 30:392–4.
34. Giorgi J, Liu Z, Hultin LE, Cumberland WG, Hennessey K, Detels R.
Elevated levels of CD38+ T cells in HIV infection add to the prognostic
value of low CD4+ T cell levels: results of 6 years of follow-up: the Los
Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune
Defic Syndr 1993; 6:904–12.
35. Schiffer V, Deveau C, Meyer L, et al. Recent changes in the management
of primary HIV-1 infection: results from the French PRIMO cohort.
HIV Med 2004; 5:326–33.
